Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study
Efti plus pembrolizumab was well-tolerated and revealed signs of antitumor activity in patients with NSCLC resistant to PD-(L)1 inhibitors, warranting further investigation. Trial registration number: NCT03625323.
Authors
- Frédéric Triebel (ORCID: https://orcid.org/0000-0002-1526-7045)
- Wade T. Iams (ORCID: https://orcid.org/0000-0003-2109-298X)
- Timothy Clay (ORCID: https://orcid.org/0000-0002-1953-2694)
- Patricia Roxburgh (ORCID: https://orcid.org/0000-0001-9869-591X)
- Margarita Majem (ORCID: https://orcid.org/0000-0002-9919-7485)
- Julio A. Peguero (ORCID: https://orcid.org/0000-0002-9464-4901)
- Martin Förster (ORCID: https://orcid.org/0000-0003-3876-7269)
- Matthew Krebs (ORCID: https://orcid.org/0000-0001-7540-3064)
- Pawan Bajaj (ORCID: https://orcid.org/0009-0002-7687-8509)
- Andrés Barba
- Christian Mueller (ORCID: https://orcid.org/0009-0001-6795-5309)
- Bernard Doger
- Suvini Perera
Institutions
- St John of God Subiaco Hospital (AU)
- University College London Hospitals NHS Foundation Trust (GB)
- Vanderbilt University (US)
- Manchester Academic Health Science Centre (GB)
- Beatson West of Scotland Cancer Centre (GB)
- Hospital de Sant Pau (ES)
- Trans Tasman Radiation Oncology Group (AU)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- The Christie NHS Foundation Trust (GB)
- Tennessee Oncology (US)
- TrueBinding (United States) (US)
- UCL Biomedical Research Centre (GB)
- Immutep (Germany) (DE)
- Hematology Oncology Consultants (US)
- University College London (GB)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1016/j.jtocrr.2024.100725
- Citations
- 9
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.54
Funders
- National Institute for Health and Care Research
- Manchester Biomedical Research Centre